Allakos Inc.
NASDAQ:ALLK
Overview | Financials
Company Name | Allakos Inc. |
Symbol | ALLK |
Currency | USD |
Price | 0.882 |
Market Cap | 78,765,318 |
Dividend Yield | 0% |
52-week-range | 0.54 - 1.69 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Robert Alexander Ph.D. |
Website | https://www.allakos.com |
An error occurred while fetching data.
About Allakos Inc.
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD